Optum’s CEO Just Named the Real Problem in Healthcare AI

At HealthEx, one of the clearest observations about the future of healthcare came through a pharmacy workflow example shared by Optum CEO Dr. Patrick Conway.

He described a scenario in which a medication was covered and clinically appropriate, but the process still broke down because the necessary information was unavailable at the right point in the workflow. In the legacy version of that process, the patient discovered the issue at the pharmacy. The pharmacist had limited ability to resolve it. The physician was contacted after the fact. The payer absorbed the frustration. The failure was less about clinical appropriateness than information timing.

The redesigned workflow changed when the missing information surfaced. Instead of allowing the issue to appear at the pharmacy counter, the system identified it inside the prescriber’s workflow. According to Conway, the median time for that process moved from eight hours to less than thirty seconds. The operational significance is not simply speed. It is earlier detection.

This example points to a broader thesis: the highest-value applications of AI in healthcare will be measured by their ability to reduce late-stage operational failure.

Healthcare inefficiency is often framed around administrative cost, staffing burden, or payer complexity. Those are valid explanations, but they are incomplete. Many failures in healthcare are also temporal. The system identifies missing information after a patient has arrived, after care has been scheduled, after a claim has been submitted, after discharge planning has become urgent, or after a family has already absorbed the burden of uncertainty.

Late detection changes the nature of the problem. A missing data field becomes a delay. A documentation gap becomes a denial. A discharge barrier becomes an avoidable bed day. A coverage question becomes a patient trust issue.

For this reason, the next generation of healthcare technology should be evaluated less by whether it automates an isolated task and more by whether it improves the timing, routing, and resolution of operational risk. The strategic question is whether a system can identify a preventable failure while there is still enough context, authority, and time to resolve it cleanly.

This has implications for how healthcare organizations adopt AI. Tools that sit outside existing workflows may create new work even when they solve a narrow problem. More durable value is likely to come from technology that fits into the actual sites of decision-making: the prescribing workflow, the scheduling workflow, the authorization workflow, the discharge workflow, the pharmacy workflow, and the revenue cycle workflow.

Conway’s broader comments also suggest that the future of healthcare infrastructure will depend on partnership across payers, providers, pharmacies, technology organizations, and scaled healthcare platforms. In highly fragmented systems, AI cannot create value only by being technically capable. It has to be operationally situated.

The more important question is whether large healthcare organizations can use their scale to reduce friction before it reaches the patient. Scale, in this context, should be evaluated by its ability to coordinate information across physical health, behavioral health, pharmacy, social needs, and financial navigation.

The central lesson from HealthEx is that healthcare AI should be judged by how effectively it changes the timing of failure. When problems are surfaced earlier, they can be resolved with less labor, less escalation, and less patient harm. When they surface late, even small issues become expensive and emotionally costly.

The future of healthcare may depend less on whether organizations adopt AI and more on whether they use it to intervene at the moment when the system can still prevent the failure from becoming the patient’s problem.